Halozyme Therapeutics HALO EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Halozyme Therapeutics’s 10-Q, filed November 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's EV / EBITDA?
- Halozyme Therapeutics (HALO) reported EV / EBITDA of 13× in Q3 2025.
- How has Halozyme Therapeutics's EV / EBITDA changed year-over-year?
- Halozyme Therapeutics's EV / EBITDA decreased by 27.0% year-over-year, from 17.8× to 13×.
- What is the long-term trend for Halozyme Therapeutics's EV / EBITDA?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's EV / EBITDA has grown at a -24.8% compound annual growth rate (CAGR), from 41.7× to 13.4×.
- What does EV / EBITDA mean?
- What the whole business (debt included) costs relative to its operating cash earnings.
- How do you interpret EV / EBITDA?
- Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
- How does EV / EBITDA compare across companies?
- Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.